Navigation Links
Vinorelbine in Medical News

Mayo Clinic Researchers Say Triple Drug Combination is Promising Option to Treat Metastatic HER2+ Breast Cancer

...b -- always causes hair loss, Dr. Tan says. All of the agents are approved for use by the U.S. Food and Drug Administration for cancer, although vinorelbine has not been approved for this particular treatment regimen in the U.S., the researchers say. Capecitabine chemotherapy is not usually paired wit...

Triple drug combination is promising option to treat metastatic HER2+ breast cancer

...uzumab always causes hair loss, Dr. Tan says. All of the agents are approved for use by the U.S. Food and Drug Administration for cancer, although vinorelbine has not been approved for this particular treatment regimen in the U.S., the researchers say. Capecitabine chemotherapy is not usually paired with t...

Twenty New Abstracts on Oral Xeloda(R) (capecitabine) Featured at the 31st San Antonio Breast Cancer Symposium

...treated with oral Xeloda monotherapy compared with vinorelbine monotherapy in one study or gemcitabine monotherap...total health care costs than patients treated with vinorelbine monotherapy or gemcitabine monotherapy. Th...py-related expenditures than those associated with vinorelbine in women with metastatic breast cancer (Lead Autho...

Chemo for Mesothelioma Offers Limited Survival Benefits

... mitomycin, vinblastine and cisplatin every three weeks or one injection of vinorelbine every week for 12 weeks) in addition to active symptom control (ACS) treatm...l survival or quality of life. However, exploratory analyses suggested that vinorelbine merits further investigation," the authors concluded. More information ...

Other highlights in the April 8 JNCI

... failed to respond to the initial two cycles of TAC were randomly assigned to either four additional cycles of TAC or four cycles of capecitabine plus vinorelbine (NX). Increasing the number of TAC cycles or switching regimens did not appear to improve outcomes. Only 5.3 percent of women on TAC achieved a comple...

Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.'s Drug Pipeline

...D., presented the phase III results of XYOTAX in first-line treatment of non-small cell lung cancer noting that "equivalent survival to gemcitabine or vinorelbine in poor performance status patients and the reduction in toxicity coupled with the convenience of administration is very important and it's on the bas...

Gene Screening Points Way to More Effective Chemotherapy

...The researchers then re-tested the six genes that showed the most dramatic effect with paclitaxel and tried the same test using the chemotherapy drugs vinorelbine (Navelbine) and gemcitabine (Gemzar), but the results were not as dramatic as those seen for paclitaxel. “Our studies using additional drugs indicate ...

Trails to detect effective breast cancer drugs that reduces recurrences

...started to determine and help patients to have a recurrence free survival after breast cancer surgery. The chemotherapy drugs docetaxel (Taxotere) and vinorelbine (Navelbine) are tested to analyze the outcomes.// It was previously reported by the Finnish researchers that patients who received infusions of tr...

Treatment of Breast Cancer with Herceptin for Nine Weeks

...searchers to analyze the safety and efficiency of Herceptin in 1010 women who had breast cancer. The women included in the study received docetaxel or vinorelbine and then FEC (5-fluorouracil, epirubicin, cyclophosphamide).Those whose HER-2 protein were increased Herceptin was given for nine weeks or no Hercepti...

Enhancing Survival Rate Of Lung Cancer Patients

...ycles of cisplatin-based chemotherapy or observation. In addition to cisplatin, the drug etoposide was given to about 56 percent of patients; the drug vinorelbine was given to about 26 percent of patients; vinblastine was given to 11 percent of patients, and vindesine was given to nearly 6 percent of patients. O...
Vinorelbine in Medical Technology

Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology

Results are basis for CTI's Marketing Authorization Application currently under review by the EMEA SEATTLE, July 7 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC ; MTA) today announced the publication of results from its randomized phase III trial ...

XYOTAX More Cost Effective With Fewer Side Effects Than Gemcitabine or Vinorelbine in Treating Non-Small Cell Lung Cancer

ASCO publication highlights health care cost benefit of bioengineering paclitaxel CHICAGO, June 05, 2007 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) announced that data published in the 2007 Annual Meeting of the American Society of Clinical Oncology (ASCO) abstracts showed reduced med...

More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies

...d at SABCS include: RAD001 Multicenter Phase I clinical trial of daily and weekly RAD001 (everolimus) in combination with vinorelbine and trastuzumab in HER-2-overexpressing metastatic breast cancer with prior resistance to trastuzumab ( SABCS Abstract #406: Friday, December 12, 200...

Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments

... clinical trial of daily and weekly RAD001 (everolimus) in combination with vinorelbine and trastuzumab in patients with HER2-overexpressing metastatic breast canc...RAD001 (20 mg, 30 mg, 50 mg and 70 mg) regimens. Patients were administered vinorelbine (25 mg/m2, IV over 10-15 min on days 1 and 8 q3w) and trastuzumab (4 mg/kg ...

ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study

...fusion site reactions with emulsion formulation of vinorelbine (ANX-530) compared to vinorelbine solution," will be published in the 2008 Proceedin...and pleased that our goal to improve the safety of vinorelbine has been observed in the clinic," stated Evan M. L...

European Regulatory Agency Accepts Cell Therapeutics, Inc.'s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review

...rial, single-agent XYOTAX resulted in comparable survival to gemcitabine or vinorelbine in first-line patients and, with the exception of neuropathy known to be as...2 patients with NSCLC. STELLAR 4 tested XYOTAX versus either gemcitabine or vinorelbine for the potential first-line treatment of PS2 patients with NSCLC. While th...

Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)

...rial, single-agent XYOTAX resulted in comparable survival to gemcitabine or vinorelbine in first-line patients and, with the exception of neuropathy known to be as...2 patients with NSCLC. STELLAR 4 tested XYOTAX versus either gemcitabine or vinorelbine for the potential first-line treatment of PS2 patients with NSCLC. About ...

ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study

...n. Worldwide annual sales of Navelbine and generic vinorelbine in 2006 were approximately $200 million. The bioe...lsion) ANX-530 is a novel emulsion formulation of vinorelbine tartrate, a generic chemotherapy agent. ANX-530 is...from intravenous-delivery of vinorelbine tartrate. vinorelbine tartrate works by disrupting microtubule formation...

ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study

...vel, emulsion formulation of vinorelbine tartrate. vinorelbine tartrate, marketed under the brand name Navelbine(...n. Worldwide annual sales of Navelbine and generic vinorelbine in 2006 were approximately $200 million. "Complet...lsion) ANX-530 is a novel emulsion formulation of vinorelbine tartrate, a generic chemotherapy agent. ANX-530 is...

Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy

..., the median time to first disease progression in the patients treated with vinorelbine was only 4.4 months. Values for "prostate-specific antigen" (PSA), an est...ve, Open Label, Randomized Phase II Trial of Weekly Docetaxel Versus Weekly vinorelbine as First Line Chemotherapy in Patients with Androgen Independent Prostate C...
Vinorelbine in Biological Technology

ADVENTRX Provides Update on Strategic Transaction Process

... About ANX-530 (vinorelbine emulsion) ANX-530 is a novel emulsion formulation of the chemotherapy drug vinorelbine. ANX-530 emulsifies vinorelbine into a homogeneous suspension of nanoparticles that is designed to protect the venous endothelium during administration into a peripheral vein. Navel...

ADVENTRX Announces Further Cost-Cutting Measures

...2010. About ANX-530 (vinorelbine emulsion) ANX-530 is a novel emulsion formulation of the chemotherapy drug vinorelbine. ANX-530 emulsifies vinorelbine into a homogeneous suspension of nanoparticles that is designed to protect the venous endothelium during administration into a peripheral vein. Navel...

ADVENTRX Announces Restructuring and Cost Reduction Initiatives

...e same link. About ANX-530 (vinorelbine emulsion) ANX-530 is a novel emulsion formulation of the chemotherapy drug vinorelbine. ANX-530 emulsifies vinorelbine into a homogeneous suspension of nanoparticles that is designed to protect the venous endothelium during administration into a peripheral vein. Navelb...

ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study

...lence observed between an emulsion formulation of vinorelbine (ANX-530) and vinorelbine solution in a clinical study of patients with advanced cancer," was present...tic breast cancer. Worldwide sales of Navelbine and generic formulations of vinorelbine in 2006 were in excess of $200 million. Navelbine and its generic equival...

ADVENTRX Creates Executive Vice President Position and Announces New Chief Financial Officer

...ime to be joining the ADVENTRX management team," stated Mr. Bagnall. "The company has made tremendous progress with its novel emulsion formulations of vinorelbine and docetaxel. I look forward to the continued development and anticipated commercialization of these product candidates, as well as the continued dev...

Complete ANX-530 Safety Data to be Published in the 2008 Proceedings of the American Society of Clinical Oncology

...fusion site reactions with emulsion formulation of vinorelbine (ANX-530) compared to vinorelbine solution," will ...ide sales of Navelbine and generic formulations of vinorelbine in 2006 were in excess of $200 million. Navelbin...jection site reactions. Our formulation emulsifies vinorelbine into a homogeneous suspension of nanoparticles tha...

ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting

...alence observed between an emulsion formulation of vinorelbine (ANX-530) and vinorelbine solution in a clinical s...ection site reactions from intravenous delivery of vinorelbine tartrate. Vinorelbine tartrate works by disrupting...the vinca alkaloid class of antineoplastic agents. vinorelbine is indicated as a single agent or in combination w...

Cell Therapeutics, Inc. (CTI) to Submit Marketing Authorization Application for XYOTAX(TM) for First-line Non-small Cell Lung Cancer Ahead of Schedule

... within six weeks. Most physicians will utilize single-agent gemcitabine or vinorelbine to treat these frail patients. Current treatments also have limited effecti...ELLAR 4 phase III clinical trial tested XYOTAX versus either gemcitabine or vinorelbine for the potential first-line treatment of poor performance status (PS2) pat...

ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results

...atment of metastatic colorectal cancer," stated Evan M. Levine, chief executive officer of ADVENTRX. "We are encouraged by continued progress with our vinorelbine emulsion product candidate ANX-530 and our docetaxel emulsion product candidate ANX-514. We expect that our emulsion product candidates will require l...

ADVENTRX Appoints Vice President of Commercialization

...lsion) ANX-530 is a novel emulsion formulation of vinorelbine tartrate, a generic chemotherapy agent. ANX-530 is...nd severity of vein irritation from IV-delivery of vinorelbine tartrate. Vinorelbine tartrate works by disrupting...the vinca alkaloid class of antineoplastic agents. vinorelbine is indicated as a single agent or in combination w...
Other Tags
(Date:12/19/2014)... Tampa, FL (PRWEB) December 19, 2014 ... Celliant Revitalizing Bedsheets are now available. Celliant, the ... in both sheets and pillowcases. , There are ... clinically proven additional circulation, increased oxygenation and balanced ... quality, faster healing and pain relief; enhanced athletic ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 SuperCloset raises ... SuperClone Rooms. SuperCloset continues to offer indoor growers the ... one of the new SuperClone Rooms with the award ... and turnkey indoor hydroponic grow room setup. , The ... world, SuperCloset’s SuperPonic SuperCloner 50 . ...
(Date:12/19/2014)... 20, 2014 An evening dress is perfect ... lady’s closet. Discount-Dress.com, a distinguished dresses retailer, has unveiled its ... dresses in this great shopping platform. Customers can ... staff's hard work, Discount-Dress.com has been accepted and praised by ... and easier shopping stage for clients. In order to expand ...
(Date:12/19/2014)... research warns parents that buying an older car for their teens ... teen drivers killed in the United States between 2008 and 2012 ... often lacked important safety features that are available on newer cars, ... crashes were in cars at least six years old, 34 percent ... in cars 11 to 15 years old, and 17 percent were ...
(Date:12/19/2014)... 2014 (HealthDay News) -- Potentially illness-causing E. coli bacteria ... farmers markets, according to a new study. Researchers ... from 13 farmers markets in Los Angeles and Orange ... of almost 150 samples tested, 24 percent were positive ... according to the researchers. Both types of bacteria ...
Breaking Medicine News(10 mins):Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2Health News:Attractive Evening Dresses Announced by Discount-Dress.com 2Health News:Older Cars a Bad Choice for Younger Drivers 2Health News:E. Coli Germs Found on Farmers Market Herbs 2
(Date:12/19/2014)... 18, 2014 Research and Markets ( ... "Micro Market Monitor: North America Perimeter Security Systems Market" ... http://photos.prnewswire.com/prnh/20130307/600769 The North American perimeter ... of 3.6% from 2014 to 2019. Although the U.S. ... Canada is expected to grow at ...
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ... "Samsung Galaxy S5 - Home Button Synaptics Fingerprint ... http://photos.prnewswire.com/prnh/20130307/600769 ... than the iPhone 5S, Samsung introduces for the ... The Galaxy S5 home button presents ...
(Date:12/17/2014)... RALEIGH, N.C. , Dec. 16, 2014 ... has licensed its PerformTek biometric technology to industry leaders ... their highly accurate, clinically validated, biometric wearable products. These ... January 6-9 in Las Vegas . ... the technology is accurate, flexible and robust – with ...
Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
Other Contents